

## XP-002151142

AN - 1989-312197 [43]

A - [001] 014 04- 525 55& 642 645

AP - JP19880054037 19880308

CPY - AJIN

DC - A96 B04

FS - CPI

IC - A61K37/16 ; C07K5/08 ; C07K7/06 ; C07K99/00

KS - 0231 2766 3265

MC - A12-V01 A12-W11L B04-C01A B04-C01B B07-D03 B07-D09 B10-B02D B10-B02E  
B12-F04

M1 - [03] F012 F014 F423 F521 H1 H100 H101 H181 H182 H401 H481 J0 J011 J012  
J1 J111 J171 J371 M280 M312 M313 M315 M320 M321 M331 M332 M340 M342  
M343 M349 M371 M381 M391 M423 M510 M520 M521 M530 M540 M620 M630 M640  
M650 M710 M903 P525 V902 V911 V921; 1704-X 1724-X 1711-X 1714-X 8929-0  
- [04] F012 F423 G013 G100 H1 H100 H181 H401 H441 J0 J011 J012 J1 J111  
J171 J371 K0 L2 L250 M280 M312 M314 M320 M321 M332 M333 M340 M342 M343  
M349 M371 M381 M391 M423 M510 M520 M521 M530 M531 M540 M620 M630 M640  
M650 M710 M903 P525 V902 V911 V912 V921; 1704-X 1724-X 1711-X 1714-X  
8929-0

M2 - [01] G013 G019 G100 H1 H100 H181 H4 H402 H442 H5 H598 H8 H9 J0 J013 J1  
J171 J3 J372 M210 M211 M271 M281 M312 M313 M321 M322 M332 M343 M349  
M371 M381 M391 M392 M414 M510 M520 M532 M540 M630 M640 M650 M710 M903  
M904 P525 V0 V902 V911 V921; 8943-17001-N; 1704-X 1724-X 1711-X 1714-X  
8929-0

- [02] F011 F012 F014 F019 F423 F499 F521 H100 H181 H401 H481 J0 J013 J1  
J111 J3 J311 J371 J372 M280 M312 M313 M321 M322 M331 M332 M340 M342  
M343 M349 M371 M381 M391 M392 M413 M510 M521 M522 M530 M540 M630 M640  
M650 M710 M903 M904 P525 V0 V902 V911 V921; 8943-17002-N; 1704-X  
1724-X 1711-X 1714-X 8929-0

PA - (AJIN ) AJINOMOTO KK

PN - JP1226898 A 19890911 DW198943 006pp

PR - JP19880054037 19880308

XA - C1989-138069

XIC - A61K-037/16 ; C07K-005/08 ; C07K-007/06 ; C07K-099/00

AB - J01226898 Specific peptides contg. 65 aminoacids and hypotensives  
contg. the peptide are new.

- USE/ADVANTAGE - They are used as hypertensives. The hypertensive is in  
the form of tablets, capsules, granules, powder, syrup, suspension,  
suppository, ointment, cream, gel or injection preparation. The dose  
of the peptide is 0.001-1000 mg, pref. 0.01-10 mg day. (In an  
example) prep. of Lys-Thr-Ala-Pro: comprises Fmoc-Pro resin (302g)  
(p-alkoxybenzylalcohol resin introduced with 0.53 mil mol/g of  
Fmoc-Pro OH) is suspended in DMF (20 ml) and treated with a washing  
cycle for the Fmoc radical removal:(0/0)

CN - 8943-17001-N 8943-17002-N

DRL - 1704-X 1711-X 1714-X 1724-X 8929-0

IW - NEW PEPTIDE HYPERTENSIVE CONTAIN PEPTIDE COMPRISE PRO CAN ADMINISTER  
VARIOUS ROUTE

IKW - NEW PEPTIDE HYPERTENSIVE CONTAIN PEPTIDE COMPRISE PRO CAN ADMINISTER  
VARIOUS ROUTE

NC - 001

OPD - 1988-03-08

ORD - 1989-09-11

PAW - (AJIN ) AJINOMOTO KK

TI - New peptide and hypertensives contg. peptide - e.g. comprising  
lys-thr-ala-pro, which can be administered by various routes